Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-in-Pentetreotide. Addendum
Abstract
Somatostatin (SST) is a peptide hormone implicated in the growth and progression of cancers and SSTR2 is the predominant receptor subtype expressed in breast cancer. We hope to study the pattern of expression and clinical significance of SSTR2 levels in breast cancer. We have developed an algorithm called AQUA that can assess protein expression on tissue microarrays (TMA) based on molecular co-localization techniques. Our results show that SSTR2 is localized predominantly to the malignant cells although also in vessel/lymphatic elements. Although expression was not significantly correlated with survival on our TMA it did appear to be overexpressed compared with benign breast tissue. A vessel compartment has been developed using a multiplexing protocol for co-localization of SSTR2 to tumor and endothelium concurrently. Cell line controls have also been developed to generate a reference standard curve and to use as a normalization feature. Whole sections analysis with SSTR2 also show that while heterogeneity of expression is present it is modest.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2008
- Accession Number
- ADA487987
Entities
People
- David L Rimm
- Gina G. Chung
Organizations
- Yale University